Detalhe da pesquisa
1.
Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235513
2.
Day 100 Natural Killer Cell/CD14+HLA-DRDIM ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation.
Clin Transplant
; 38(1): e15211, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38041479
3.
Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes.
Haematologica
; 108(11): 3025-3032, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37102592
4.
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
Am J Hematol
; 98(3): 464-471, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36629030
5.
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Br J Haematol
; 195(2): 201-209, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34341990
6.
Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.
Hematol Oncol
; 39(5): 658-663, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34453851
7.
Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience.
Biol Blood Marrow Transplant
; 26(12): 2217-2222, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32818553
8.
Characteristics of late transplant-associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation.
Am J Hematol
; 95(10): 1170-1179, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32618000
9.
Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia.
Am J Hematol
; 95(3): 274-281, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31814157
10.
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Blood
; 129(26): 3419-3427, 2017 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28424162
11.
Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma.
Am J Hematol
; 94(7): 786-793, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31006875
12.
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Am J Hematol
; 94(3): 291-298, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30516868
13.
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Biol Blood Marrow Transplant
; 24(6): 1187-1195, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29410180
14.
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution.
Blood
; 127(16): 1960-6, 2016 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26837698
15.
End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET.
Haematologica
; 108(6): 1697-1701, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546451
16.
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.
Haematologica
; 108(8): 2249-2254, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36601982
17.
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Br J Haematol
; 179(1): 50-60, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28653407
18.
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Br J Haematol
; 178(3): 427-433, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28466487
19.
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.
Blood
; 126(3): 328-35, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-25921059
20.
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.
Am J Hematol
; 92(5): 448-453, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-28211162